Addressing Preclinical Gaps to Prevent Biotech Trial Delays | Applied Clinical Trials Online

Addressing Preclinical Gaps to Prevent Biotech Trial Delays

Gain insight into why early toxicology readiness and strong scientific collaboration with CRO partners are critical to accelerating trial startup and regulatory approval.

In a recent video interview with Applied Clinical Trials, Ben Edwards, chief operating officer, Avance Clinical, discussed common challenges in biotech, emphasizing the importance of addressing preclinical package gaps to avoid delays.

He highlighted the need for CROs with deep scientific capabilities to create a sound scientific argument for new drugs.

In the current funding climate, he stressed the importance of obtaining patient data early to inform decision-making. Edwards also noted the shift towards adaptive trial designs and the benefits of staying with the same CRO for continuity.

Effective coordination across functions requires integrated teams and data visualization.

Author summary: Accelerating biotech trials requires early toxicology readiness.

more

Applied Clinical Trials Online Applied Clinical Trials Online — 2025-10-15

More News